| 1 | Prognostic biomarkers of intracerebral hemorrhage identified using |
|----|--|
| 2 | targeted proteomics and machine learning algorithms |
| 3 | |
| 4 | Short title: Predictive biomarkers of ICH: Unveiling insights with proteomics & |
| 5 | machine learning |
| 6 | |
| 7 | Authors: Shubham Misra ^{1,2} , Yuki Kawamura ^{2,3} , Praveen Singh ⁴ , Shantanu Sengupta ⁴ , |
| 8 | Manabesh Nath ¹ , Zuhaibur Rahman ⁴ , Pradeep Kumar ¹ , Amit Kumar ^{1,5} , Praveen |
| 9 | Aggarwal ⁶ , Achal K. Srivastava ¹ , Awadh K. Pandit ¹ , Dheeraj Mohania ⁷ , Kameshwar |
| 10 | Prasad ¹ , Nishant K. Mishra ² , Deepti Vibha^{1*} |
| 11 | |
| 12 | Affiliations: |
| 13 | ¹ Department of Neurology, All India Institute of Medical Sciences, New Delhi, India |
| 14 | ² Department of Neurology, Yale University School of Medicine, New Haven, CT |
| 15 | ³ School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom |
| 16 | ⁴ CSIR-Institute of Genomics and Integrative Biology, New Delhi, India |
| 17 | ⁵ Department of Laboratory Medicine, Rajendra Institute of Medical Sciences, Ranchi, |
| 18 | India |
| 19 | ⁶ Department of Emergency Medicine, All India Institute of Medical Sciences, New Delhi, |
| 20 | India |
| 21 | ⁷ Department of Dr. RP Centre, All India Institute of Medical Sciences, New Delhi, India |
| 22 | |
| 23 | Corresponding author details: |
| 24 | |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Prof. Dr. Deepti Vibha

- 26 DM (Neurology, AIIMS, New Delhi), MSc (Clinical Epidemiology, Erasmus MC,
- 27 Netherlands)
- 28 Professor of Neurology
- 29 Room No.: 707, 7th Floor
- 30 Neurosciences Centre, Department of Neurology,
- 31 All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
- **32 PH:** +91-11-26594485
- 33 **Email ID:** deeptivibha@gmail.com
- 34
- 35 Word Count: 2942
- 36 Total tables: 5
- 37 **Total figures:** 4
- 38 Keywords: Intracerebral Hemorrhage; Proteomics; Blood biomarkers; Prognosis;
- 39 Mortality; Poor outcome.

41

42 Abstract

Early prognostication of patient outcomes in intracerebral hemorrhage (ICH) is critical 43 for patient care. We aim to investigate protein biomarkers' role in prognosticating 44 45 outcomes in ICH patients. We assessed 22 protein biomarkers using targeted proteomics in serum samples obtained from the ICH patient dataset (N=150). We defined poor 46 47 outcomes as modified Rankin scale score of 3-6. We incorporated clinical variables and protein biomarkers in regression models and random forest-based machine learning 48 49 algorithms to predict poor outcomes and mortality. We report Odds Ratio (OR) or Hazard Ratio (HR) with 95% Confidence Interval (CI). We used five-fold cross-validation and 50 51 bootstrapping for internal validation of prediction models. We included 149 patients for 90-day and 144 patients with ICH for 180-day outcome analyses. In multivariable logistic 52 regression, UCH-L1 (aOR 9.23; 95%CI 2.41-35.33), alpha-2-macroglobulin (5.57; 1.26-53 24.59), and Serpin-A11 (9.33; 1.09-79.94) were independent predictors of 90-day poor 54 outcome; MMP-2 (6.32; 1.82-21.90) was independent predictor of 180-day poor 55 outcome. In multivariable Cox regression models, IGFBP-3 (aHR 2.08; 1.24-3.48) 56 predicted 90-day and MMP-9 (1.98; 1.19-3.32) predicted 180-day mortality. Using 57 machine learning, UCH-L1 and APO-C1 predicted 90-day mortality, and UCH-L1, MMP-9, 58 59 and MMP-2 predicted 180-day mortality. Overall, random forest models outperformed regression models for predicting 180-day poor outcomes (AUC 0.89), and 90-day (AUC 60 0.81) and 180-day mortality (AUC 0.81). Serum biomarkers independently predicted 61 short-term poor outcomes and mortality after ICH. Further research utilizing a multi-62 omics platform and temporal profiling is needed to explore additional biomarkers and 63 64 refine predictive models for ICH prognosis.

66 Abbreviations:

- 67 ICH: Intracerebral Hemorrhage; IVH: Intraventricular hemorrhage; OR: Odds Ratio; HR:
- 68 Hazard Ratio; CI: Confidence Interval; IQR: Interquartile range; AUC: Area Under the
- 69 Curve; NIHSS: National Institutes of Health Stroke Scale; GCS: Glasgow Coma Scale; mRS:
- 70 modified Rankin Scale; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; TLC:
- 71 Total Leucocyte Count; RBS: Random Blood Sugar; A2M: Alpha-2-Macroglobulin, UCH-L1:
- 72 Ubiquitin carboxyl-terminal hydrolase isozyme L1; MMP: Matrix Metalloproteinase; APO:
- Apolipoprotein; IGFBP-3: Insulin-like growth factor-binding protein-3.

75 Introduction

76 Intracerebral hemorrhage (ICH) comprises 10-15% of all strokes [1], with one-month mortality of 40%, rendering it the deadliest stroke subtype [2]. It is a significant 77 healthcare challenge worldwide, and its impact is particularly pronounced in developing 78 79 nations like India. Limited healthcare resources, disparities in access to care, and unique demographic and epidemiological factors exacerbate the burden of ICH in these regions 80 81 [3]. Understanding factors influencing ICH patient outcomes is crucial for optimizing clinical management, risk stratification, and resource allocation. While various clinical 82 83 scores exist for predicting functional outcomes and mortality in ICH [4], such as the widely-used ICH score,⁵ their accuracy for outcomes beyond hospital discharge or 30 84 85 days remains uncertain. Hence, there is a critical need for robust prediction models that integrate new predictor variables to improve ICH prognostication [5]. Serum biomarkers 86 87 have emerged as promising candidates with the potential to enhance outcome prognostication in ICH patients [6]. Integrating serum biomarkers with clinical variables 88 in prediction models may provide additional prognostic information and guide treatment 89 decisions. 90

Therefore, we undertook this study to build prognostic models using protein biomarkers
to predict poor functional outcomes and mortality in ICH patients within 24 hours of
symptom onset utilizing targeted proteomics, regression modeling, and machine learning
approaches.

95

96 Methods

97 Study sample

We used clinical and proteomic data lodged within a prospective cohort study from acollaborative effort of the Department of Neurology, All India Institute of Medical

100 Sciences (AIIMS), and the Institute of Genomics and Integrative Biology in New Delhi, India. The study database includes consecutive ICH patients aged ≥ 18 years, recruited 101 102 between 04 October 2017 and 20 March 2020 within 24 hours of symptom onset. The 103 details of this study protocol are reported in prior publications [7,8]. We obtained written informed consent from all the recruited patients or their legally authorized 104 105 representatives prior to collecting blood samples and clinical history. The study was approved by the Local Institutional Ethics Committee of AIIMS, New Delhi (Ref. No. 106 107 IECPG-395/28.09.2017).

108

109 Outcomes

We defined poor outcomes as a modified Rankin Scale (mRS) score of 3-6. Our second
outcome measure was mortality. The outcomes were ascertained by a researcher blinded
to clinical data using telephonic interviews at 90 and 180 days post-ICH.

113

114 Blood sample collection

Five ml of peripheral blood sample was taken in serum vacutainer tubes from ICH patients. For serum collection, it was left standing at room temperature for 30 minutes until clotted. It was then centrifuged at 3000g for 10 minutes, after which the serum was separated into cryovials. Five aliquots of each sample (100µl) were prepared and stored at -80°C until further analysis.

120

121 Sample preparation

Ten μl of serum samples were used for protein precipitation. To 90μl of 1X Phosphate
Buffer Saline (PBS), 10 μl serum was added and vortex mixed. Protein precipitation was
performed using pre-chilled acetone. Briefly, to 100 μl protein extract, four times volume

of pre-chilled acetone was added, vortex mixed and centrifuged at 15000 g for 10 minutes
at 4°C. The supernatant was discarded, and the protein pellets were air-dried at room

temperature and suspended in 0.1 M Tris-HCl with 8M urea, pH 8.5. Protein quantitation

- 128 was performed using the Bradford assay.
- 129

130 Reduction, Alkylation, and Trypsin Digestion

A total of 20 μg of protein from each sample was reduced with 25 mM of Dithiothreitol
(DTT) for 30 minutes at 60°C, followed by alkylation using 55 mM of Iodoacetamide (IAA)
at room temperature (in the dark) for 30 minutes. These samples were then subjected to
trypsin digestion in an enzyme to substrate ratio of 1:10 (trypsin: protein) for 16-18
hours at 37°C. Finally, the tryptic peptides were vacuum dried in vacuum concentrator.

136

Peptide selection for Multiple Reaction Monitoring (MRM)-based targeted proteomics

Peptide selection was performed using search results from ProteinPilot [9], PeptideAtlas
[10] or in-silico generated peptides of proteins using Expasy PeptideCutter tool [11].
Peptides with +2 and +3 charges were considered for MRM and for each peptide, 5-6
fragment ions were used for identification (Table S1).

143

144 Multiple Reaction Monitoring (MRM) data acquisition

145 Tryptic peptides obtained after digestion were desalted using reversed phase cartridges 146 Oasis HLB cartridge (Waters, Milford, MA) according to the following procedure: wet 147 cartridge with $1 \times 1,000 \mu l$ of 100% acetonitrile, equilibrate with $1 \times 1,000 \mu l$ of 0.1% 148 formic acid, load acidified digest, washed peptides with $1 \times 1,000 \mu l$ of 0.1% formic acid 149 and elute with $1 \times 1000 \mu l$ of 70% acetonitrile in 0.1% formic acid. The peptide mixture

150 was dried using a vacuum centrifuge, and the peptides were resuspended in 0.1% formic 151 acid at a final concentration of 1 μ g/ μ l. A heavy labeled peptide for Apo A1 152 (QGLLPVLESF**K**; **K**=Lysine-13C6,15N2) protein was spiked-in the resolubilized plasma 153 digest at a final concentration of 1 ng/ μ l.

154 The targeted MRM-MS [12] analysis of the tryptic peptides was performed on a TSQ

155 Altis (Thermo Fisher, San Jose, CA). The instrument was equipped to an H-ESI ion source.

156 A spray voltage of 3.5 keV was used with a heated ion transfer tube set at a temperature

157 of 325°C. Chromatographic separations of peptides were performed on Vanquish UHPLC

158 system (Thermo Fisher, San Jose, CA).

159 The 10 μ l of the sample was injected and peptides were loaded on an ACQUITY UPLC BEH

160 C18 column (130Å, 1.7 μm, 2.1 mm X 100 mm, Waters) from a cooled (4 °C) autosampler

161 and separated with a linear gradient of water (buffer A) and acetonitrile (buffer B),

162 containing 0.1% formic acid, at a flow rate of 300 μl/minute in 30 minutes gradient run

163 with the buffer conditions given in Table S2.

The mass spectrometer was operated in Selected Reaction Monitoring (SRM) mode. For SRM acquisitions, the first quadrupole (Q1) and the third quadrupole (Q3) were operated at 0.7 and 0.7 unit mass resolution, respectively. A dwell time of 6.175 milliseconds (ms) was chosen, and acquisitions occurred over the whole gradient of 30 minutes. Argon was used as the collision gas at a nominal pressure of 1.5 mTorr. Optimized collision energies were used for each peptide.

170

171 Bioinformatic and Statistical analyses

We analyzed the MRM-based targeted proteomics data using Skyline version 21.1 [13].
Peptide areas were spike-in normalized using a heavy labeled peptide for Apo A1 protein
and log₂ transformed. Peptides with <10% missing values were imputed using a random-

forest-based missing value imputation method. Non-biological experimental variationswere removed through batch correction.

Our study adhered to the Transparent reporting of a multivariable prediction model for 177 individual prognosis or diagnosis (TRIPOD) guidelines [14]. We performed univariable 178 179 logistic regression analysis using odds ratio (OR) and 95% confidence interval (CI) to assess poor outcomes during follow-up. Mortality rates were evaluated through Kaplan-180 181 Meier survival curves, and we constructed simple Cox proportional hazard models with hazard ratios (HR) and 95% CI. We conducted receiver operating characteristic (ROC) 182 183 curve analyses and determined optimal cut-off points for each biomarker using the 184 Youden Index (sensitivity + specificity-1).

185 Regression-based ICH outcome prediction models: We developed prediction models to determine independent predictors of poor outcomes and mortality in ICH. Variables with 186 p-value <0.1 in the univariable analysis, along with demographic variables like age and 187 sex, were included in a backward stepwise multiple logistic regression or multiple Cox 188 regression analyses. Multicollinearity among predictor variables was assessed using the 189 variance inflation factor (VIF), and predictors with a VIF value exceeding 2.5 were 190 removed from the model. We evaluated the discrimination ability using the area under 191 192 the curve (AUC) or c-statistic.

Machine Learning-based ICH outcome prediction models: We employed a random forestbased machine learning algorithm to identify additional predictors. Categorical data were encoded in binary form, while continuous data were standardized based on the population mean and standard deviation following log-normalization for skewed distributions. Train-test splits were executed in a 7:3 ratio, and random forest models with 1000 estimators were trained using the scikit-learn package. This process was repeated 1000 times, with each iteration involving a new random seed to choose the top

| 200 | 10 variables for prediction. Shapley values were computed using the SHAP package, and |
|-----|--|
| 201 | absolute means were utilized to evaluate variable importance. |
| 202 | Internal validation: We internally validated our prediction models using bootstrapping |
| 203 | and 5-fold cross-validation. |
| 204 | We conducted statistical analyses using STATA software (Version 18) and R version 3.6.2. |
| 205 | We conducted interaction network and enrichment analyses of significant biomarkers |
| 206 | using Cytoscape version 3.10.0. |
| 207 | |
| 208 | Data availability |
| 209 | The mass spectrometry proteomics data have been deposited to the ProteomeXchange |
| 210 | Consortium via the PRIDE [15] partner repository with the dataset identifier PXD032917. |
| 211 | |
| 212 | Results |
| 213 | The study cohort included 150 ICH patients recruited within 24 hours of ICH onset. Loss |
| 214 | to follow-up at 90 days was 5% (n=1), and at 180 days was 7.33% (n=6). Therefore, we |
| 215 | included 149 patients for the 90-day and 144 for the 180-day outcome analyses. |
| 216 | |
| 217 | Poor outcome at 90-day and 180-day |
| 218 | Of 149 ICH patients, 110 (73.82%) had a poor outcome at 90 days, and of 144 ICH |
| 219 | patients, 97 (67.36%) had a poor outcome at 180 days. See Table 1 for clinical variables |
| 220 | and Table S3 for protein biomarkers significantly associated with poor outcomes in the |
| 221 | univariable analysis (p<0.1). |
| 222 | Multivariable logistic regression identified lower UCH-L1 (adjusted OR 9.23; 95%CI 2.41- |
| 223 | 35.33), higher alpha-2-macroglobulin (aOR 5.57, 95%CI 1.26-24.59) and Serpin A11 |

levels (aOR 9.33; 95%CI 1.09-79.94) as independent predictors of 90-day poor outcome;

whereas higher MMP-2 levels (aOR 6.32, 95%CI 1.82-21.90) independently predicted
180-day poor outcome among other clinical predictors. The models had an AUC of 0.95
at 90 days and 0.92 at 180 days (Figure 1a, b and Table 3).

Top 10 important predictors identified by random forest algorithms for 90-day outcome
included NIHSS score, ICH volume, age, UCH-L1, platelet count, RBS, alpha-2macroglobulin, TLC, serpin A11, and haptoglobin (Figure 2a). Top 10 important
predictors of 180-day poor outcome included NIHSS score, ICH volume, TLC, age, alpha2-macroglobulin, creatinine, blood urea, UCH-L1, Serpin A11, and time taken to reach
hospital (Figure 2b).

234

235 Mortality at 90-day and 180-day

Mortality at 90 days was observed in 62 (41.61%) of 149 ICH patients and at 180 days in 67 (46.53%) of 144 ICH patients. See Table 2 for clinical variables and Table S4 for protein biomarkers significantly associated with mortality in the univariable analysis (p<0.1).

Multivariable Cox regression analysis identified lower IGFBP-3 levels (aHR 2.08; 95%CI
1.24-3.48) at 90 days and lower MMP-9 levels (aHR 1.98; 95%CI 1.19-3.32) at 180 days
as independent predictors of mortality. The models had an AUC of 0.83 at 90 days and
0.81 at 180 days (Figure 1c, d and Table 3).

Top 10 predictors of 90-day mortality identified by random forest algorithms included
NIHSS score, ICH volume, age, TLC, intraventricular extension, RBS, potassium, UCH-L1,
hemoglobin, and APO-C1 (Figure 2c). Top 10 predictors of 180-day mortality included
NIHSS score, ICH volume, age, TLC, intraventricular extension, UCH-L1, MMP-9,
potassium, MMP-2, and RBS (Figure 2d).

250 Internal validation of prediction models

Five-fold cross-validation and bootstrapping revealed that prediction models constructed with the random forest algorithm outperformed multivariable logistic and Cox regression in predicting poor outcomes at 180-day and mortality at both time points. However, there was a marginal difference in the mean AUC values of regression models and random forest models for predicting 90-day poor outcomes (Table 4, Figure S1).

256

257 Validation of previous ICH prediction models

We validated previously published ICH prediction scores, including ICH score, MICH score, ICH-FOS score, and ICH-GS score. These scores had AUCs ranging from 0.80 to 0.86 for predicting poor outcomes at 90 days and from 0.76 to 0.84 at 180 days. For mortality prediction, the AUCs ranged from 0.78 to 0.81 at 90 days and from 0.76 to 0.80 at 180 days. Adding biomarkers to the prediction models in this study improved the prediction of poor outcomes compared to previous models, but no difference was noted in models predicting mortality (Table 5).

265

266 Interaction network and enrichment analyses

267 In univariable analysis, we analyzed a protein network of 10 biomarkers linked to poor 268 outcomes and mortality post-ICH. This network featured ten biomarkers (nodes) with eight interactions (edges), including six highly connected biomarkers. MMP-9 displayed 269 the highest degree of interaction, connecting with four other proteins. In our network, 7 270 out of 8 interactions had a score exceeding 0.80, with the most robust interaction score 271 of 0.96 between MMP-2 and IGFBP-3 (Figure S2). The significant pathways encompassed 272 273 negative regulation of catalytic activity, protein metabolic processes, extracellular space, and extracellular matrix disassembly (Table S5). 274

275

276 Discussion

Our analysis reaffirms the relevance of established clinical variables in predicting poor 277 outcomes and mortality in ICH, including age, GCS score, ICH volume, NIHSS score, and 278 279 various laboratory investigations, underscoring their significance in clinical practice [16,17]. Furthermore, our analyses of 22 protein biomarkers and clinical features noted 280 281 in 24 hours post-ICH revealed UCH-L1, alpha-2-macroglobulin, Serpin A11, and MMP-2 as independent predictors of poor outcome. IGFBP-3 and MMP-9 independently 282 283 predicted mortality following ICH. Machine learning-based random forest models identified additional predictors, including haptoglobin for poor outcomes and UCH-L1, 284 285 APO-C1, and MMP-2 for mortality prediction. Integrating protein biomarkers to clinical prediction models may enhance the precision of risk assessment and resource allocation 286 287 in stroke prevention programs [18], promoting more efficient resource allocation targeting individuals most likely to develop ICH. 288

Our study reveals inconsistent optimal values for sensitivity and specificity in biomarker cutoffs from univariable analyses (Tables S3 and S4). This emphasizes the need to consider multiple biomarkers and their cutoff values for improved accuracy and reliability in ICH outcome prediction.

This study, conducted in a tertiary care center in India, holds particular significance due to the diverse demographic, genetic, and environmental factors unique to the Indian population. Understanding stroke in this context contributes to a more holistic understanding of the disease and its multifaceted risk factors, which is vital as India and many other developing nations face an increasing burden of stroke [19]. These findings can be pivotal in shaping stroke treatment and outcome prognostication strategies unique to India and similar resource-limited settings.

300 UCH-L1's association with poor outcomes in ICH suggests its potential as an early 301 neurological damage marker [20]. Alpha-2-macroglobulin's role in predicting poor 302 outcomes in ICH, previously unexplored, may relate to its involvement in protease 303 inhibition and inflammation regulation [21]. Serpin A11's anti-inflammatory and anti-304 fibrotic properties may signify a response to mitigate damage after ICH [22]. IGFBP-3's downregulation in ICH could reflect a compromised injury response [23]. The role of 305 306 APO-C1 and haptoglobin in ICH prognostication, reported for the first time in our study, requires further investigation. 307

MMP-2 and MMP-9, implicated in tissue remodeling and inflammation [24], highlight extracellular matrix dynamics in ICH pathogenesis [25]. Indeed, our network and enrichment analyses underscored MMP-9's central role in ICH pathophysiology (Figure S2), particularly its involvement in extracellular matrix-related pathways influencing ICH outcomes (Table S6) [25]. MMP-9's association with short-term mortality but not poor functional outcomes aligns with previous Indian population findings [26], suggesting potential for MMP-9 inhibition as a neuroprotective strategy in ICH [27].

Prediction models are limited by the risk of overfitting to the training data, potentially 315 compromising their generalizability. Cross-validation and bootstrapping address this by 316 assessing model performance across different data subsets and testing stability through 317 318 resampling. We, therefore, internally validated our findings through five-fold cross-319 validation and bootstrapping, demonstrating that random forest models consistently 320 outperformed regression models in predicting 180-day poor outcome and 90-day and 180-day mortality, as evidenced by higher AUC values (Table 4). This suggests that 321 machine learning algorithms, with their ability to capture complex interactions and 322 323 patterns, offer a valuable tool for enhancing prognostic accuracy in ICH [28,29].

We also validated the performance of previously published prediction scores for ICH outcomes (Table S5). Our study, demonstrated higher AUC values for poor outcome predictions compared to the existing prediction scores. This suggests that integrating novel protein biomarkers and clinical features in our model enhances the precision of risk assessment for ICH outcomes.

The choice of outcomes in this study emphasizes the importance of patient-reported 329 330 outcome measures (PROMs) and quality of life in stroke research and care [30]. While many clinical trials prioritize mortality as the primary outcome, it's essential to 331 332 acknowledge that survival alone may not fully represent the patient's overall well-being or quality of life [31]. Rankin 4-5 indicates significant disability, and for many patients, 333 334 this level of impairment can be as debilitating as death itself. Rankin 3 signifies moderate disability that can significantly affect a patient's independence and quality of life. By 335 consolidating mRS scores 3-6, our study essentially encompasses all patients 336 experiencing death or significant disability. 337

Compared to previous studies, our study has several strengths. Firstly, we utilized a targeted proteomics approach, specifically multiple reaction monitoring, for precise and sensitive measurement of protein biomarkers. Secondly, we recruited patients within the 24-hour window, a critical period for stroke management, allowing earlier biomarker assessment than prior studies [26,32]. Thirdly, our study had minimal loss to follow-up (<5%).

However, our study also has several limitations. Firstly, the small sample size warrants external validation of these biomarkers in adequately powered studies. However, we internally validated our dataset and obtained consistent AUCs across the outcome measures. Secondly, our study only included patients from a single center, limiting its generalizability. Thirdly, focusing on a 24-hour time window may not capture the full ICH

progression, necessitating earlier biomarker measurements [33,34] and exploring temporal changes. Lastly, we provided relative quantification data for protein biomarkers, suggesting the need for obtaining absolute quantification values in future studies.

353

354 Conclusion

355 These data reflect outcomes in developing nations underscoring the potential of serum

- biomarkers, in conjunction with clinical variables, to enhance outcome prediction in ICH
- 357 patients. Biomarkers like UCH-L1, alpha-2-macroglobulin, Serpin A11, MMP-2, IGFBP-3,
- and MMP-9 showed strong associations with outcomes, improving model accuracy. With
- 359 better performance of random forest-based machine learning models, proteomic data
- 360 holds promise for ICH prognostication. Future research should examine temporal profiles
- 361 of these biomarkers in larger cohorts and explore additional pathways using multi-omics
- 362 platforms to refine predictive models for ICH prognosis.
- 363

364 Competing Interests

- 365 The authors have declared that no competing interests exist.
- 366

367 Acknowledgements

- 368 S. Misra was a DST-INSPIRE Fellow supported by Department of Science and Technology,
- 369 Government of India.

370

371 Study Funding

This study was supported in part by the AIIMS Intramural Research Grant (F. No. 8762/A-762/2019/RS).

374

375 Ethics Approval

The study was approved by the local institutional ethics committee of AIIMS, New Delhi (Ref. No. IECPG-395/28.09.2017). We obtained written informed consent from all the recruited patients or their legally authorized representatives prior to collecting blood samples and clinical history.

380

Author Contributions: DV conceptualized the idea of this research topic, helped design 381 382 the clinical methodology, and supervised each step of execution of this study. SM primarily conducted each step of this study ranging from blood sample collection, 383 384 processing, proteomic experimentation, statistical and proteomic data analysis, building 385 prediction models, results interpretation, and manuscript writing. YK conducted the 386 machine learning analysis. SSG supervised the proteomic experimentation and its data analysis. SM and PS conducted the proteomic experiments and data analysis. ZR 387 contributed in conducting the proteomic experimentations in the study. MN contributed 388 in patient sample collection and processing. AK, PK, and NKM helped in statistical data 389 390 analysis. DV, PA, AKS, AKP, DM, and KP aided in patient recruitment for this study. All authors contributed to the article and approved the submitted version. 391

393 References

- Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147: e93–e621.
 doi:10.1161/CIR.00000000001123
- An SJ, Kim TJ, Yoon B-W. Epidemiology, Risk Factors, and Clinical Features of
 Intracerebral Hemorrhage: An Update. J Stroke. 2017;19: 3–10.
- 400 doi:10.5853/jos.2016.00864
- Pandian JD, Padma Srivastava MV, Aaron S, Ranawaka UK, Venketasubramanian N,
 Sebastian IA, et al. The burden, risk factors and unique etiologies of stroke in
 South-East Asia Region (SEAR). Lancet Reg Health Southeast Asia. 2023;17:
 100290. doi:10.1016/j.lansea.2023.100290
- 405 4. Gregório T, Pipa S, Cavaleiro P, Atanásio G, Albuquerque I, Chaves PC, et al.
 406 Prognostic models for intracerebral hemorrhage: systematic review and meta-407 analysis. BMC Med Res Methodol. 2018;18: 145. doi:10.1186/s12874-018-0613-8
- Wartenberg KE, Hwang DY, Haeusler KG, Muehlschlegel S, Sakowitz OW, Madžar D,
 et al. Gap Analysis Regarding Prognostication in Neurocritical Care: A Joint
 Statement from the German Neurocritical Care Society and the Neurocritical Care
 Society. Neurocrit Care. 2019;31: 231–244. doi:10.1007/s12028-019-00769-6
- Troiani Z, Ascanio L, Rossitto CP, Ali M, Mohammadi N, Majidi S, et al. Prognostic
 Utility of Serum Biomarkers in Intracerebral Hemorrhage: A Systematic Review.
 Neurorehabil Neural Repair. 2021;35: 946–959.
 doi:10.1177/15459683211041314
- 416 7. Misra S, Singh P, Sengupta S, Kushwaha M, Rahman Z, Bhalla D, et al. Subtyping
 417 strokes using blood-based biomarkers: A proteomics approach. medRxiv; 2023. p.
 418 2023.06.10.23291233. doi:10.1101/2023.06.10.23291233
- 419 8. Misra S, Singh P, Nath M, Bhalla D, Sengupta S, Kumar A, et al. Blood-based protein
 420 biomarkers for the diagnosis of acute stroke: A discovery-based SWATH-MS
 421 proteomic approach. Front Neurol. 2022;13: 989856.
 422 doi:10.3389/fneur.2022.989856
- **423** 9. Seymour SL, Hunter CL. ProteinPilot[™] Software overview. : 5.
- 424 10. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, et al. The
 425 PeptideAtlas project. Nucleic Acids Res. 2006;34: D655-658.
 426 doi:10.1093/nar/gkj040
- 427 11. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, et al.
 428 Protein identification and analysis tools in the ExPASy server. Methods Mol Biol.
 429 1999;112: 531–552. doi:10.1385/1-59259-584-7:531
- 430 12. Zhang H, Liu Q, Zimmerman LJ, Ham A-JL, Slebos RJC, Rahman J, et al. Methods for
 431 peptide and protein quantitation by liquid chromatography-multiple reaction

| 432 | monitoring mass spectrometry. Mol Cell Proteomics. 2011;10: M110.006593 |
|-----|---|
| 433 | doi:10.1074/mcp.M110.006593 |

- 434 13. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al.
 435 Skyline: an open source document editor for creating and analyzing targeted
 436 proteomics experiments. Bioinformatics. 2010;26: 966–968.
 437 doi: 10.1002 (bioinformatics 0.10054)
- doi:10.1093/bioinformatics/btq054
- 438 14. Collins GS, Reitsma JB, Altman DG, Moons KGM, TRIPOD Group. Transparent
 439 reporting of a multivariable prediction model for individual prognosis or diagnosis
 440 (TRIPOD): the TRIPOD statement. The TRIPOD Group. Circulation. 2015;131: 211–
 441 219. doi:10.1161/CIRCULATIONAHA.114.014508
- Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et
 al. The PRIDE database and related tools and resources in 2019: improving support
 for quantification data. Nucleic Acids Res. 2019;47: D442–D450.
 doi:10.1093/nar/gky1106
- Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a
 simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32: 891–
 897. doi:10.1161/01.str.32.4.891
- 449 17. Morotti A, Phuah C-L, Anderson CD, Jessel MJ, Schwab K, Ayres AM, et al. Leukocyte
 450 Count and Intracerebral Hemorrhage Expansion. Stroke. 2016;47: 1473–1478.
 451 doi:10.1161/STROKEAHA.116.013176
- 452 18. Mishra NK, Khadilkar SV. Stroke program for India. Ann Indian Acad Neurol.
 453 2010;13: 28–32. doi:10.4103/0972-2327.61273
- 454 19. GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, Cercy K,
 455 Johnson CO, Alam T, et al. Global, Regional, and Country-Specific Lifetime Risks of
 456 Stroke, 1990 and 2016. N Engl J Med. 2018;379: 2429–2437.
 457 doi:10.1056/NEJMoa1804492
- 458 20. Yu W-H, Wang W-H, Dong X-Q, Du Q, Yang D-B, Shen Y-F, et al. Prognostic
 459 significance of plasma copeptin detection compared with multiple biomarkers in
 460 intracerebral hemorrhage. Clin Chim Acta. 2014;433: 174–178.
 461 doi:10.1016/j.cca.2014.03.014
- 462 21. Vandooren J, Itoh Y. Alpha-2-Macroglobulin in Inflammation, Immunity and
 463 Infections. Front Immunol. 2021;12: 803244. doi:10.3389/fimmu.2021.803244
- Yan B, Luo L, Liu L, Wang Z, Chen R, Wu Y, et al. Serpin family proteins as potential
 biomarkers and therapeutic drugs in stroke: A systematic review and metaanalysis on clinical/preclinical studies. CNS Neurosci Ther. 2023;29: 1738–1749.
 doi:10.1111/cns.14205
- Siddiqui EM, Mehan S, Bhalla S, Shandilya A. Potential role of IGF-1/GLP-1 signaling
 activation in intracerebral hemorrhage. Curr Res Neurobiol. 2022;3: 100055.
 doi:10.1016/j.crneur.2022.100055

471 24. Misra S, Talwar P, Kumar A, Kumar P, Sagar R, Vibha D, et al. Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: 472 A systematic review and meta-analysis of 29 studies. Gene. 2018;672: 180–194. 473 doi:10.1016/j.gene.2018.06.027 474

- 25. Li H, Ghorbani S, Ling C-C, Yong VW, Xue M. The extracellular matrix as modifier of 475 476 neuroinflammation and recovery in ischemic stroke and intracerebral hemorrhage. Neurobiol Dis. 2023;186: 106282. doi:10.1016/j.nbd.2023.106282 477
- 478 26. Sagar R, Kumar A, Verma V, Yadav AK, Raj R, Rawat D, et al. Incremental Accuracy of Blood Biomarkers for Predicting Clinical Outcomes After Intracerebral 479 Hemorrhage. J Stroke Cerebrovasc Dis. 2021;30: 105537. 480 doi:10.1016/j.jstrokecerebrovasdis.2020.105537 481
- 482 27. Dang B, Duan X, Wang Z, He W, Chen G. A Therapeutic Target of Cerebral 483 Hemorrhagic Stroke: Matrix Metalloproteinase- 9. Curr Drug Targets. 2017;18: 484 1358-1366. doi:10.2174/1389450118666170427151657
- 28. Guo R, Zhang R, Liu R, Liu Y, Li H, Ma L, et al. Machine Learning-Based Approaches 485 for Prediction of Patients' Functional Outcome and Mortality after Spontaneous 486 487 Intracerebral Hemorrhage. J Pers Med. 2022;12: 112. doi:10.3390/jpm12010112
- 488 29. Fernandez-Lozano C, Hervella P, Mato-Abad V, Rodríguez-Yáñez M, Suárez-Garaboa S, López-Dequidt I, et al. Random forest-based prediction of stroke outcome. Sci 489 490 Rep. 2021;11: 10071. doi:10.1038/s41598-021-89434-7
- 30. Reeves M, Lisabeth L, Williams L, Katzan I, Kapral M, Deutsch A, et al. Patient-491 492 Reported Outcome Measures (PROMs) for Acute Stroke: Rationale, Methods and 493 Future Directions. Stroke. 2018;49: 1549–1556. 494 doi:10.1161/STROKEAHA.117.018912
- 495 31. Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate 496 into benefits for patients. Trials. 2017;18: 122. doi:10.1186/s13063-017-1870-2
- 497 32. Ebinger M, Ipsen N, Leonards CO, Empl L, Hanne L, Liman T, et al. Circulating 498 insulin-like growth factor binding protein-3 predicts one-year outcome after 499 ischemic stroke. Exp Clin Endocrinol Diabetes. 2015;123: 461–465. doi:10.1055/s-0035-1554632 500
- 501 33. Misra S, Kumar A, Kumar P, Yadav AK, Mohania D, Pandit AK, et al. Blood-based 502 protein biomarkers for stroke differentiation: A systematic review. Proteomics Clin 503 Appl. 2017;11. doi:10.1002/prca.201700007
- 504 34. Misra S, Montaner J, Ramiro L, Arora R, Talwar P, Nath M, et al. Blood biomarkers 505 for the diagnosis and differentiation of stroke: A systematic review and meta-506 analysis. Int J Stroke. 2020;15: 704–721. doi:10.1177/1747493020946157
- 35. Cho D-Y, Chen C-C, Lee W-Y, Lee H-C, Ho L-H. A new Modified Intracerebral 507 508 Hemorrhage score for treatment decisions in basal ganglia hemorrhage--a 509 randomized trial. Crit Care Med. 2008;36: 2151-2156. doi:10.1097/CCM.0b013e318173fc99 510

- 511 36. Ji R, Shen H, Pan Y, Wang P, Liu G, Wang Y, et al. A novel risk score to predict 1-year functional outcome after intracerebral hemorrhage and comparison with existing 512 scores. Crit Care. 2013;17: R275. doi:10.1186/cc13130 513
- 37. Ruiz-Sandoval JL, Chiquete E, Romero-Vargas S, Padilla-Martínez JJ, González-514
- Cornejo S. Grading scale for prediction of outcome in primary intracerebral 515
- hemorrhages. Stroke. 2007;38: 1641-1644. doi:10.1161/STROKEAHA.106.478222 516

518 **Figure Legends**

519

- **Figure 1:** ROC curves to predict (a) 90-day poor outcome, (b) 180-day poor outcome, (c)
- 521 90-day mortality, and (d) 180-day mortality in multivariable analysis of ICH patients.

522

- 523 **Figure 2:** Absolute mean Shapely values calculated for random forest-based machine
- 524 learning algorithms to predict (a) 90-day poor outcome, (b) 180-day poor outcome, (c)

525 90-day mortality, and (d) 180-day mortality in ICH.

526

- **Figure 3:** ROC curves for five-fold cross validation of multivariable regression models to
- 528 predict (a) 90-day poor outcome, (b) 180-day poor outcome, (c) 90-day mortality, and529 (d) 180-day mortality in ICH.

530

Figure 4: Protein-protein interaction network analysis of significant protein biomarkers
that can predict poor functional outcome and mortality after ICH using the Cytoscape
software. The colour of nodes and edges represents the degree of interaction and
interaction score.

| Characteristics | 90-day poor | 90-day good | p-value | 180-day poor | 180-day good | p-value |
|---------------------------------------|-----------------|----------------|---------|----------------|----------------|---------|
| | outcome (N=110) | outcome (N=39) | | outcome (N=97) | outcome (N=47) | |
| Age (years) ^a | 60 (50-66) | 48 (42-55) | <0.001 | 60 (50-66) | 50 (45-60) | 0.004 |
| Male ^b | 66 (60) | 32 (82.05) | 0.02 | 58 (59.79) | 36 (76.60) | 0.05 |
| Female ^b | 44 (40) | 7 (17.95) | _ | 39 (40.21) | 11 (23.40) | - |
| Blood sampling time from onset | 17 (12-20.3) | 17.5 (7.5-20) | 0.57 | 17.2 (12-20.3) | 16 (8-20) | 0.33 |
| (hours) ^a | | | | | | |
| Time taken to reach hospital | 4.71 (2.5-9) | 5 (1.5-9.83) | 0.70 | 4.5 (2.5-9) | 5 (1-9.8) | 0.55 |
| (hours) ^a | | | | | | |
| Any surgical procedure ^b | 25 (22.73) | 1 (2.56) | 0.02 | 24 (24.74) | 2 (4.26) | 0.008 |
| Antihypertensives ^b | 31 (28.18) | 12 (30.77) | 0.76 | 29 (29.90) | 11 (23.40) | 0.42 |
| ACE inhibitors ^b | 0 | 1 (2.56) | N.E. | 0 | 1 (2.13) | N.E. |
| ARB ^b | 6 (5.45) | 3 (7.69) | 0.62 | 6 (6.19) | 3 (6.38) | 0.96 |
| Beta blockers ^b | 31 (28.18) | 13 (33.33) | 0.55 | 31 (31.96) | 13 (27.66) | 0.60 |
| Calcium channel blockers ^b | 43 (39.09) | 22 (56.41) | 0.06 | 38 (39.18) | 24 (51.06) | 0.18 |
| Diuretics ^b | 66 (60) | 16 (41.03) | 0.04 | 58 (59.79) | 24 (51.06) | 0.32 |

Table 1: Baseline characteristics and univariable analyses of poor outcomes at 90-day and 180-day after intracerebral hemorrhage.

| Hypertension ^b | 69 (62.73) | 29 (74.36) | 0.19 | 65 (67.01) | 29 (61.70) | 0.53 |
|--|----------------|------------|---------|--------------|-------------|--------|
| Diabetes ^b | 23 (20.91) | 6 (15.38) | 0.46 | 23 (23.71) | 4 (8.51) | 0.04 |
| Dyslipidemia ^b | 9 (8.18) | 1 (2.56) | 0.25 | 9 (9.28) | 1 (2.13) | 0.15 |
| Myocardial Infarction ^b | 1 (0.91) | 1 (2.56) | 0.46 | 1 (1.03) | 1 (2.13) | 0.61 |
| Atrial fibrillation ^b | 3 (2.73) | 0 | N.E. | 2 (2.06) | 0 | N.E. |
| Current Smoking ^b | 27 (24.55) | 14 (35.90) | 0.17 | 23 (23.71) | 16 (36.17) | 0.19 |
| Mild alcohol intake ^b | 9 (8.18) | 4 (10.26) | 0.69 | 8 (8.25) | 5 (10.64) | 0.64 |
| Moderate alcohol intake ^b | 4 (3.64) | 3 (7.69) | 0.31 | 2 (2.06) | 5 (10.64) | 0.04 |
| Heavy alcohol intake ^b | 8 (7.27) | 7 (17.95) | 0.07 | 7 (7.22) | 6 (12.77) | 0.28 |
| No Exercise ^b | 86 (78.18) | 31 (79.49) | 0.86 | 76 (78.35) | 37 (78.72) | 0.96 |
| Low Education ^b | 88 (80) | 26 (66.67) | 0.09 | 79 (81.44) | 32 (68.09) | 0.08 |
| Low socio-economic status ^b | 39 (35.45) | 13 (33.33) | 0.81 | 32 (32.99) | 17 (36.17) | 0.71 |
| Obesity ^b | 12 (10.91) | 6 (15.38) | 0.46 | 11 (11.34) | 6 (12.77) | 0.80 |
| ICH Volume (ml) ^a | 36 (22.2-58.2) | 15 (9-25) | < 0.001 | 37 (22.2-60) | 18 (9.5-35) | <0.001 |
| Intraventricular Hemorrhage ^b | 47 (42.73) | 7 (17.95) | 0.008 | 45 (46.39) | 9 (19.15) | 0002 |
| Deep ICH ^b | 87 (79.09) | 36 (92.31) | 0.07 | 79 (81.44) | 39 (82.98) | 0.82 |
| Lobar ICH ^b | 16 (14.55) | 2 (5.13) | 0.14 | 13 (13.40) | 5 (10.64) | 0.64 |

| SBP (mmHg) ^a | 177.5 (154-196) | 170 (150-194) | 0.72 | 180 (154-196) | 170 (152-192) | 0.13 |
|--|--------------------|-------------------|--------|-------------------|-------------------|---------|
| DBP (mmHg) ^a | 100 (88-110) | 100 (90-113) | 0.44 | 100 (88-112) | 100 (90-110) | 0.67 |
| NIHSS score at admission ^a | 23 (15-28) | 10 (8-14) | <0.001 | 23 (18-28) | 10 (7-15) | <0.001 |
| GCS score at admission ^a | 8 (5-11) | 15 (11-15) | <0.001 | 8 (4-11) | 15 (11-15) | < 0.001 |
| mRS score at discharge ^a | 5 (4-6) | 4 (3-4) | <0.001 | 5 (4-6) | 4 (3-4) | <0.001 |
| RBS (mg/dl) ^a | 155.21 (126-190) | 142 (109-168) | 0.02 | 152.14 (129-185) | 152.14 (116- | 0.09 |
| | | | | | 176.47) | |
| TLC (10 ³ /µL) ^a | 10540 (9100- | 9440 (7990- | 0.01 | 11000 (9300- | 9500 (7700- | <0.001 |
| | 13796.29) | 11022.33) | | 14100) | 10910) | |
| Hemoglobin (g/dl) ^a | 12.66 (11.3-14.1) | 13.6 (12.52-14.6) | 0.12 | 12.61 (11.2-14.2) | 13.54 (12.4-14.5) | 0.09 |
| Platelets (10 ³ /µL) ^a | 172 (126.2-201.39) | 200 (167-254) | 0.09 | 177.67 (131-220) | 177.67 (134-243) | 0.87 |
| Blood Urea (mg%) ^a | 35.5 (25-45) | 27 (20-40.11) | 0.13 | 39.62 (26-46.49) | 28 (21-40.11) | 0.008 |
| Creatinine (mg%) ^a | 1 (0.8-1.4) | 0.93 (0.7-1.2) | 0.44 | 1.02 (0.83-1.5) | 0.9 (0.7-1.1) | 0.007 |
| Potassium (mM/L) ^a | 4 (3.7-4.47) | 3.84 (3.5-4.31) | 0.14 | 4 (3.6-4.4) | 3.9 (3.7-4.37) | 0.66 |
| Sodium (mM/L) ^a | 139.13 (136-142) | 139.2 (136-141) | 0.72 | 139.1 (136-142) | 139.5 (136-142) | 0.79 |
| Total Bilirubin (mg%) ^a | 0.75 (0.6-1.05) | 0.8 (0.6-1) | 0.73 | 0.75 (0.6-1.05) | 0.75 (0.6-1.04) | 0.91 |

a: Variables represented as Median (IQR), b: Variables represented as frequency (percentage).

| Characteristics | 90-day death | 90-day alive | p-value | 180-day death | 180-day alive | p-value |
|---|---------------|--------------|---------|---------------|---------------|---------|
| | (N=62) | (N=87) | | (N=67) | (N=77) | |
| Age (years) ^a | 62 (50-70) | 50 (45-60) | < 0.001 | 62 (50-70) | 50 (45-60) | 0.001 |
| Male ^b | 34 (54.84) | 64 (73.56) | 0.02 | 38 (56.72) | 56 (72.73) | 0.02 |
| Female ^b | 28 (45.16) | 23 (26.44) | - | 29 (43.28) | 21 (27.27) | |
| Blood sampling time from onset (hours) ^a | 17 (10-20.3) | 17 (9.5-20) | 0.78 | 17 (9.8-20.5) | 17 (11.5-20) | 0.74 |
| Time taken to reach hospital (hours) ^a | 4.1 (2.3-8.5) | 5 (1.5-9.8) | 0.22 | 4.2 (2.3-8.5) | 5 (1.5-9.8) | 0.33 |
| Any surgical procedure ^b | 14 (22.58) | 12 (13.79) | 0.22 | 15 (22.39) | 11 (14.29) | 0.27 |
| Antihypertensives ^b | 16 (25.81) | 27 (31.03) | 0.41 | 18 (26.87) | 22 (28.57) | 0.52 |
| ACE inhibitors ^b | 0 | 1 (1.15) | N.E. | 0 | 1 (1.30) | N.E. |
| ARB ^b | 3 (4.84) | 6 (6.90) | 0.60 | 4 (5.97) | 5 (6.49) | 0.86 |
| Beta blockers ^b | 15 (24.19) | 29 (33.33) | 0.33 | 19 (28.36) | 25 (32.47) | 0.73 |
| Calcium channel blockers ^b | 22 (35.48) | 43 (49.43) | 0.12 | 24 (35.82) | 38 (49.35) | 0.11 |
| Diuretics ^b | 34 (54.84) | 48 (55.17) | 0.79 | 38 (56.72) | 44 (57.14) | 0.99 |
| Hypertension ^b | 41 (66.13) | 57 (65.52) | 0.87 | 46 (68.66) | 48 (62.34) | 0.69 |
| Diabetes ^b | 16 (25.81) | 13 (14.94) | 0.09 | 16 (23.88) | 11 (14.29) | 0.10 |

Table 2: Baseline characteristics and univariable analyses of mortality at 90-day and 180-day after intracerebral hemorrhage.

| Dyslipidemia ^b | 5 (8.06) | 5 (5.75) | 0.36 | 6 (8.96) | 4 (5.19) | 0.25 |
|--|----------------|---------------|---------|------------------|---------------|--------|
| Myocardial Infarction ^b | 0 | 2 (2.30) | N.E. | 0 | 2 (2.60) | N.E. |
| Atrial fibrillation ^b | 0 | 3 (3.45) | N.E. | 0 | 2 (2.60) | N.E. |
| Current Smoking ^b | 13 (20.97) | 28 (32.18) | 0.15 | 16 (23.88) | 23 (29.87) | 0.36 |
| Mild alcohol intake ^b | 4 (6.45) | 9 (10.34) | 0.34 | 4 (5.97) | 9 (11.69) | 0.25 |
| Moderate alcohol intake ^b | 2 (3.23) | 5 (5.75) | 0.39 | 2 (2.99) | 5 (6.49) | 0.33 |
| Heavy alcohol intake ^b | 2 (3.23) | 13 (14.94) | 0.05 | 2 (2.99) | 11 (14.29) | 0.04 |
| No Exercise ^b | 50 (80.65) | 67 (77.01) | 0.36 | 53 (79.10) | 60 (77.92) | 0.49 |
| Low Education ^b | 52 (83.87) | 62 (71.26) | 0.12 | 55 (82.09) | 56 (72.73) | 0.22 |
| Low socio-economic status ^b | 19 (30.65) | 33 (37.93) | 0.44 | 20 (29.85) | 29 (37.66) | 0.42 |
| Obesity ^b | 8 (12.90) | 10 (11.49) | 0.69 | 8 (11.94) | 9 (11.69) | 0.79 |
| ICH Volume (ml) ^a | 40.4 (29.9-70) | 22 (10.75-40) | < 0.001 | 39.2 (27.6-66.3) | 22 (10.8-40) | <0.001 |
| Intraventricular Hemorrhage ^b | 35 (56.45) | 19 (21.84) | < 0.001 | 37 (55.22) | 17 (22.08) | <0.001 |
| Deep ICH ^b | 48 (77.42) | 75 (86.21) | 0.14 | 53 (79.10) | 65 (84.42) | 0.24 |
| Lobar ICH ^b | 10 (16.13) | 8 (9.20) | 0.21 | 10 (14.93) | 8 (10.39) | 0.31 |
| SBP (mmHg) ^a | 170 (150-190) | 180 (154-196) | 0.99 | 177 (150-196) | 173 (154-194) | 0.53 |
| DBP (mmHg) ^a | 100 (87-110) | 100 (90-120) | 0.42 | 100 (87-110) | 100 (90-113) | 0.64 |

| NIHSS score at admission ^a | 24 (18-28) | 15 (9-23) | < 0.001 | 24 (18-28) | 14 (9-23) | <0.001 |
|--|-------------------|-----------------|---------|-----------------|-----------------|--------|
| GCS score at admission ^a | 7 (4-10) | 13 (8-15) | < 0.001 | 7 (4-10) | 13 (8-15) | <0.001 |
| mRS score at discharge ^a | 5 (5-6) | 4 (4-5) | < 0.001 | 5 (4-6) | 4 (4-5) | <0.001 |
| RBS (mg/dl) ^a | 164.2 (136-193) | 147 (116-172) | <0.001 | 160 (130-191.7) | 152.1 (120-173) | <0.001 |
| TLC (10 ³ /μL) ^a | 12000 (9700- | 9900 (8400- | < 0.001 | 12000 (9700- | 9900 (8418.9- | <0.001 |
| | 15750) | 11861.8) | | 15920) | 11560) | |
| Hemoglobin (g/dl) ^a | 12.6 (11-14.2) | 13.3 (12-14.3) | 0.28 | 12.6 (11-14.2) | 13.3 (12-14.2) | 0.22 |
| Platelets (10 ³ /µL) ^a | 177.7 (126.2-222) | 184 (137.6-235) | 0.54 | 177.7 (126.2- | 177.7 (137.6- | 0.98 |
| | | | | 223) | 229.4) | |
| Blood Urea (mg%) ^a | 40.06 (24-46) | 30 (23-42.88) | 0.04 | 40 (24-46) | 30 (23-42) | 0.03 |
| Creatinine (mg%) ^a | 1 (0.8-1.5) | 1 (0.7-1.2) | 0.10 | 1 (0.8-1.5) | 0.9 (0.7-1.2) | 0.07 |
| Potassium (mM/L)ª | 4.1 (3.8-4.5) | 3.9 (3.5-4.3) | 0.11 | 4 (3.8-4.5) | 3.9 (3.6-4.3) | 0.18 |
| Sodium (mM/L) ^a | 138.9 (136-141.5) | 139.6 (136-142) | 0.34 | 139 (136-141.5) | 139.6 (136-142) | 0.35 |
| Total Bilirubin (mg%)ª | 0.8 (0.6-1) | 0.8 (0.6-1) | 0.68 | 0.8 (0.6-1) | 0.8 (0.6-1) | 0.94 |

a: Variables represented as Median (IQR), b: Variables represented as frequency (percentage).

| Table 3: Multivariable prediction models | to predict poor outcome | and mortality after Intrace | rebral Hemorrhage |
|--|-------------------------|-----------------------------|-------------------|
|--|-------------------------|-----------------------------|-------------------|

| Predictor variables | OR (95% CI) | P-value | Predictor variables | HR (95% CI) | P-value |
|-----------------------|--------------------|----------|-------------------------|------------------|---------|
| 90-day poor outcome | <u> </u> | <u> </u> | 90-day mortality | 1 | |
| AUC/c-statistic: 0.95 | (0.92-0.98) | | AUC/c-statistic: 0.83 (| 0.76-0.89) | |
| Age | 1.12 (1.06-1.19) | <0.001 | RBS | 1.01 (1.00-1.01) | <0.001 |
| NIHSS score | 1.21 (1.10-1.33) | <0.001 | NIHSS score | 1.07 (1.03-1.12) | 0.002 |
| ICH volume | 1.08 (1.03-1.12) | 0.001 | IGFBP-3 (<16.48) | 2.08 (1.24-3.48) | 0.005 |
| UCH-L1 (<13.85) | 9.23 (2.41-35.33) | 0.001 | IVH | 1.90 (1.10-3.28) | 0.02 |
| A2M (>17.87) | 5.57 (1.26-24.59) | 0.02 | Age | 1.03 (1.00-1.05) | 0.03 |
| Serpin A11 (>11.36) | 9.33 (1.09-79.94) | 0.04 | Creatinine | 1.38 (1.03-1.85) | 0.03 |
| 180-day poor outcom | ie | <u> </u> | 180-day mortality | 1 | |
| AUC/c-statistic: 0.92 | (0.88-0.96) | | AUC/c-statistic: 0.81 (| 0.74-0.87) | |
| NIHSS score | 1.26 (1.16-1.36) | <0.001 | NIHSS score | 1.08 (1.03-1.12) | <0.001 |
| Creatinine | 10.44 (2.26-48.32) | 0.003 | RBS | 1.01 (1.00-1.01) | 0.005 |
| MMP-2 (>18.72) | 6.32 (1.82-21.90) | 0.004 | MMP-9 (<15.99) | 1.98 (1.19-3.32) | 0.009 |
| Age | 1.06 (1.01-1.10) | 0.02 | TLC | 1.00 (1.00-1.00) | 0.01 |
| Diabetes | 6.69 (1.40-31.94) | 0.02 | ICH volume | 1.01 (1.00-1.01) | 0.03 |
| L | 1 | 1 | | 1 | 1 |

| erate alcohol 0.06 (0.004-0.79) 0.03 |
|--------------------------------------|
| |

90-day poor outcome adjusted for age, gender, any surgical procedure, CCB, diuretic, heavy alcohol, low education, ICH volume, IVH, Deep ICH, NIHSS, RBS, TLC, HP, UCH-L1, A2M, and Serpin A11.

180-day poor outcome adjusted for age, gender, any surgical procedure, diabetes, moderate alcohol, low education, ICH volume, IVH, NIHSS, TLC, RBS, hemoglobin,

blood urea, creatinine, A2M, MINPP-1, MMP-2, and UCH-L1.

90-day mortality adjusted for age, gender, diabetes, heavy alcohol, ICH volume, IVH, NIHSS, TLC, RBS, blood urea, creatinine, APO-C1, IGFBP3, and UCH-L1.

180-day mortality adjusted for age, gender, diabetes, heavy alcohol, ICH volume, IVH, NIHSS, TLC, RBS, blood urea, creatinine, APO-C1, UCH-L1, and MMP-9.

Table 4: Five-fold cross validation and bootstrapping for internal validation of prediction

models

| Outcome measures | Logistic regression (mean | Random Forest (mean | |
|----------------------|---------------------------|---------------------|--|
| | AUC of 5-fold cross | AUC of 5-fold cross | |
| | validation) | validation) | |
| 90-day poor outcome | 0.90 (0.88-0.97) | 0.89 (0.81-0.91) | |
| 180-day poor outcome | 0.87 (0.88-0.97) | 0.89 (0.85-0.95) | |
| 90-day mortality | 0.78 (0.68-0.95) | 0.81 (0.73-0.89) | |
| 180-day mortality | 0.76 (0.68-0.86) | 0.81 (0.78-0.85) | |

| Table 5: Validation of previously published ICH prediction scores. | |
|---|--|
|---|--|

| S. No | Prediction score | 90-day poor outcome, | 180-day poor outcome, | 90-day mortality, | 180-day mortality, |
|-------|--------------------|----------------------|-----------------------|-------------------|--------------------|
| | | AUC (95% CI) | AUC (95% CI) | AUC (95% CI) | AUC (95% CI) |
| 1. | ICH score [16] | 0.81 (0.74-0.88) | 0.78 (0.71-0.86) | 0.80 (0.73-0.87) | 0.80 (0.72-0.87) |
| 2. | MICH score [35] | 0.83 (0.77-0.90) | 0.80 (0.73-0.87) | 0.81 (0.73-0.88) | 0.80 (0.73-0.87) |
| 3. | ICH-FOS score [36] | 0.86 (0.79-0.92) | 0.84 (0.77-0.91) | 0.80 (0.73-0.87) | 0.80 (0.73-0.87) |
| 4. | ICH-GS score [37] | 0.80 (0.73-0.88) | 0.76 (0.67-0.84) | 0.78 (0.71-0.85) | 0.76 (0.68-0.84) |
| 5. | Present study | 0.90 (0.88-0.97) | 0.87 (0.88-0.97) | 0.78 (0.68-0.95) | 0.76 (0.68-0.86) |

Abbreviations- ICH: Intracerebral hemorrhage; MICH- modified Intracerebral hemorrhage; ICH-FOS: Intracerebral hemorrhage- Functional Outcome Score; ICH-GS: intracerebral hemorrhage Grading Scale; AUC: Area Under the Curve; CI: Confidence Interval.

The present study's AUCs include the internally validated 5-fold cross validation AUC values from logistic regression.

ICH score: Glasgow coma scale (GCS) (15-13= 0; 12-5= 1; 4-3= 2), ICH volume ($<30 \text{ cm}^3 = 0$; $\geq 30 \text{ cm}^3 = 1$), presence of intraventricular hemorrhage (IVH) (no = 0; yes = 1), infratentorial origin (no = 0; yes = 1), age (<80 = 0; $\geq 80 = 1$).

MICH score: GCS (15-13= 0; 12-5= 1; 4-3= 2), ICH volume (≤20 cm³ = 0; 21-50 cm³ = 1; ≥51 cm³ = 2), presence of IVH or hydrocephalus (no = 0; yes = 1).

ICH-FOS score: age ($\leq 59 = 0$; 60-69 = 1; 70-79 = 2; $\geq 80 = 4$), NIH Stroke Scale (NIHSS) (0-5 = 0; 6-10 = 2; 11-15 = 3; 16-20 = 4; $\geq 21 = 5$), GCS (15-13 = 0; 12-9 = 1; 8-3 = 2), admission glucose ($\leq 11.0 \text{ mmol/L} = 0$; $\geq 11.1 \text{ mmol/L} = 1$), ICH volume for supratentorial origin ($<40 \text{ cm}^3 = 0$; 40-70 cm³ = 2; >70 cm³ = 2), ICH volume for infratentorial origin ($<10 \text{ cm}^3 = 0$; 10-20 cm³ = 2; >20 cm³ = 2), IVH (no = 0; yes = 1).

ICH-GS score: age (<45 = 1; 45-64 = 2; $\geq 65 = 3$), GCS (15-13 = 1, 12-9 = 2, 8-3 = 3), ICH location (supratentorial = 1; infratentorial = 2), ICH volume (for supratentorial origin: $<40 \text{ cm}^3 = 1$; $40-70 \text{ cm}^3 = 3$; for infratentorial origin: $<10 \text{ cm}^3 = 1$; $10-20 \text{ cm}^3 = 2$; $>20 \text{ cm}^3 = 3$).







